Global Arthralgia Drugs Market, By Drug Type (Non-steroidal anti-inflammatory (NSAID), Corticosteroids, Antidepressants, Narcotics, Anticonvulsants, Antibiotics, Others), Dosage Form (Injection, Tablets, Cream, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Any portion of a joint, including cartilage, bone, ligaments, tendons, and muscles, can cause discomfort, pain, or inflammation. Arthralgia is a term that refers to aching or pain in one or more of the body's joints. Arthralgia can be caused by a variety of things, including arthritis and other diseases, injury, infection, and an allergic reaction to medication or food. Joint inflammation is commonly treated with steroid injections. Joint aspiration is a treatment that removes fluid from the afflicted joint if it is needed (arthrocentesis). Arthralgia caused by a broken bone may necessitate surgery or the use of a cast.
Data Bridge Market Research analyses that the arthralgia drugs market was valued at USD 64.56 billion in 2021 and is expected to reach USD 89.04 billion by 2029, registering a CAGR of 4.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Non-steroidal anti-inflammatory (NSAID), Corticosteroids, Antidepressants, Narcotics, Anticonvulsants, Antibiotics, Others), Dosage Form (Injection, Tablets, Cream, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Allergan (Ireland), Abbott (US), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), Zydus Cadila (India)
|
|
Market Opportunities
|
|
Market Definition
Arthralgia is a painful condition that affects one or more joints. Sharp, dull, stabbing, scorching, or throbbing pain might occur, and its intensity can range from mild to severe. Arthralgia can be caused by a variety of factors, including injury, infection, arthritis, and other illnesses. Arthritis, or inflammation of the joints, is the most prevalent cause. Joint pain is the most common symptom of arthralgia. Joint pain can strike suddenly or gradually intensify over time.
Arthralgia Drugs Market Dynamics
Drivers
- Rise in the incidences of obesity
The surging incidences of obesity is a major factor driving the arthralgia drugs market's growth rate. Obesity puts extra strain on the knees and hips, causing the cushion joints to wear down more quickly. According to a factsheet published by the World Health Organization (WHO) in February 2018, 1.9 billion persons over 18 were overweight in 2016, with 650 million of them being obese. Obesity is considered a major risk factor causing arthralgia and hence, influencing the market dynamics during the forecast period of 2022-2029.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of arthralgia drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to a factsheet published by the Centers for Disease Control and Prevention (CDC), between 2013 and 2015, 29.3 percent of people aged 45 to 64 and 49.6 percent of people aged 65 and up were diagnosed with arthritis in the United States. Geriatrics are more susceptible to get joint pain and further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness and rising healthcare expenditure will expand the arthralgia drugs market. Additionally, sedentary lifestyle of people and increasing number of cases of rheumatoid arthritis will result in the expansion of arthralgia drugs market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the arthralgia drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the arthralgia drugs market growth during the forecast period.
Restraints/Challenges
On the other hand, the expiration of patented drugs and the introduction of generic version of drugs will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and high cost associated with drugs will challenge the arthralgia drugs market. Additionally, side effects linked with arthralgia drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This arthralgia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the arthralgia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Arthralgia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Arthralgia Drugs Market
The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had an impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The pandemic's lockdown has put a financial strain on the private healthcare industry in a number of countries. Outpatient visits, manpower, equipment, consumables, and other resources were reduced. Furthermore, the coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. Hence, the arthralgia drugs market is projected to stabilize in the future.
Global Arthralgia Drugs Market Scope
The arthralgia drugs market is segmented on the basis of drug type, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Non-steroidal anti-inflammatory (NSAID)
- Corticosteroids
- Antidepressants
- Narcotics
- Anticonvulsants
- Antibiotics
- Others
Dosage Form
- Injection
- Tablets
- Cream
- Others
Route of Administration
- Topical
- Parenteral
- Oral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Arthralgia Drugs Market Regional Analysis/Insights
The arthralgia drugs market is analyzed and market size insights and trends are provided by country, drug type, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the arthralgia drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the arthralgia drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to2029 due to surging prevalence of obesity and rising geriatric population in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Arthralgia Drugs Market Share Analysis
The arthralgia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to arthralgia drugs market.
Some of the major players operating in the arthralgia drugs market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Allergan (Ireland)
- Abbott (US)
- LEO Pharma A/S (Denmark)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Amneal Pharmaceuticals LLC. (US)
- Zydus Cadila (India)
SKU-